High-dose treatment for malignant rhabdoid tumor of the kidney: No evidence for improved survival-The Gesellschaft für Pädiatrische Onkologie und Hämatologie (GPOH) experience.
Rhoikos FurtwaenglerLeo KagerPatrick MelchiorChristian RübeMartin EbingerNasenien Nourkami-TutdibiFelix NiggliSteven WarmannJochen HubertusGabriele AmmanIvo LeuschnerChristian VokuhlNorbert GrafMichael Christoph FrühwaldPublished in: Pediatric blood & cancer (2017)
Our retrospective analysis suggests comparable outcomes for patients with and without HDSCT, if adjusted for early disease progression.